X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1122) 1122
Publication (98) 98
Newsletter (32) 32
Book Review (12) 12
Magazine Article (4) 4
Book Chapter (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
Report (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (959) 959
hiv infections - drug therapy (748) 748
male (659) 659
female (654) 654
adult (583) 583
stavudine (565) 565
stavudine - adverse effects (508) 508
anti-hiv agents - adverse effects (465) 465
infectious diseases (458) 458
stavudine - therapeutic use (384) 384
anti-hiv agents - therapeutic use (374) 374
hiv (369) 369
index medicus (358) 358
middle aged (357) 357
antiretroviral therapy (273) 273
drug therapy, combination (267) 267
immunology (262) 262
reverse transcriptase inhibitors - adverse effects (240) 240
stavudine - administration & dosage (214) 214
zidovudine (207) 207
highly active antiretroviral therapy (202) 202
cd4 lymphocyte count (199) 199
risk factors (199) 199
reverse transcriptase inhibitors - therapeutic use (195) 195
virology (194) 194
lamivudine (186) 186
hiv infection (183) 183
aids (180) 180
anti-hiv agents - administration & dosage (179) 179
hiv infections - complications (172) 172
pharmacology & pharmacy (168) 168
lamivudine - therapeutic use (162) 162
drug therapy (161) 161
therapy (159) 159
antiretroviral therapy, highly active - adverse effects (151) 151
antiviral agents (151) 151
lipodystrophy (148) 148
treatment outcome (147) 147
viral load (145) 145
lamivudine - adverse effects (144) 144
didanosine - adverse effects (138) 138
zidovudine - adverse effects (135) 135
protease inhibitors (132) 132
hiv infections - virology (131) 131
zidovudine - therapeutic use (131) 131
antiretroviral drugs (129) 129
human immunodeficiency virus--hiv (129) 129
tenofovir (126) 126
didanosine (124) 124
research (111) 111
adolescent (107) 107
toxicity (107) 107
didanosine - therapeutic use (106) 106
antiretroviral therapy, highly active (105) 105
nevirapine (103) 103
hiv patients (102) 102
hiv-infected patients (101) 101
human-immunodeficiency-virus (101) 101
reverse-transcriptase inhibitors (101) 101
reverse transcriptase inhibitors - administration & dosage (100) 100
microbiology (99) 99
health aspects (98) 98
lamivudine - administration & dosage (98) 98
nevirapine - adverse effects (97) 97
hiv protease inhibitors - adverse effects (95) 95
hiv protease inhibitors - therapeutic use (95) 95
care and treatment (92) 92
child (92) 92
nevirapine - therapeutic use (92) 92
hiv infections - immunology (91) 91
hiv-1 (91) 91
hiv-1 - drug effects (91) 91
retrospective studies (91) 91
cohort studies (90) 90
efavirenz (90) 90
prospective studies (90) 90
prevalence (87) 87
complications and side effects (86) 86
human immunodeficiency virus (84) 84
acidosis, lactic - chemically induced (83) 83
acquired immune deficiency syndrome--aids (83) 83
aged (83) 83
active antiretroviral therapy (81) 81
drugs (78) 78
lipoatrophy (78) 78
time factors (76) 76
research article (75) 75
acquired immunodeficiency syndrome - drug therapy (73) 73
cross-sectional studies (72) 72
mitochondrial toxicity (72) 72
zidovudine - administration & dosage (70) 70
adenine - analogs & derivatives (69) 69
rna, viral - blood (69) 69
abacavir (68) 68
dosage and administration (68) 68
adults (67) 67
drug administration schedule (67) 67
lactic acidosis (66) 66
didanosine - administration & dosage (65) 65
hiv infections - blood (65) 65
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1108) 1108
French (17) 17
Spanish (12) 12
German (7) 7
Japanese (5) 5
Chinese (4) 4
Italian (4) 4
Danish (2) 2
Portuguese (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal of Evidence Based Medicine and Healthcare, ISSN 2349-2562, 09/2018, Volume 5, Issue 38, pp. 2714 - 2718
BACKGROUND HIV disease is becoming increasingly prevalent. With ART being available in government ART centres and also drugs prices getting cheaper, most HIV... 
Lamivudine and Nevirapine | SLN (Stavudine | ADR (Adverse Drug Reactions). ZLN (Zidovudine | Lamivudine and Efavirenz | ATT (Anti-Tuberculous Treatment) | SLE (Stavudine | ART (Anti-Retroviral Therapy) | TLE (Tenofovir | ALT (Alanine Transferase)
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2007, Volume 45, Issue 1, pp. 34 - 42
BACKGROUND:The effects of HIV infection, highly active antiretroviral therapy (HAART), and specific antiretroviral agents on lipoproteins in women are not well... 
Low-density lipoprotein | Women | Highly active antiretroviral therapy | Lipids | High-density lipoprotein | INFECTIOUS DISEASES | lipids | high-density lipoprotein | BODY-COMPOSITION | IMMUNOLOGY | INSULIN SENSITIVITY | PROTEASE INHIBITORS | low-density lipoprotein | DIABETES-MELLITUS | NAIVE SUBJECTS | DENSITY-LIPOPROTEIN CHOLESTEROL | THERAPY | PLASMA-CONCENTRATIONS | highly active antiretroviral therapy | INFECTED PATIENTS | LOPINAVIR/RITONAVIR | women | Cholesterol - blood | Didanosine - adverse effects | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Hispanic Americans - statistics & numerical data | Nevirapine - adverse effects | Tenofovir | Adenine - therapeutic use | Stavudine - therapeutic use | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Dideoxynucleosides - adverse effects | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Organophosphonates - adverse effects | HIV Protease Inhibitors - therapeutic use | HIV-1 | Didanosine - therapeutic use | Multivariate Analysis | Lipoproteins, HDL - blood | United States | HIV Seropositivity - drug therapy | Nevirapine - therapeutic use | Lamivudine - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Stavudine - adverse effects | Lipids - blood | Adult | Anti-HIV Agents - therapeutic use | Female | Dideoxynucleosides - therapeutic use | Drug Therapy, Combination | HIV Seronegativity | Nelfinavir - therapeutic use | Fasting | Cross-Sectional Studies | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | European Continental Ancestry Group - statistics & numerical data | Benzoxazines - therapeutic use | Nelfinavir - adverse effects | African Continental Ancestry Group - statistics & numerical data | Triglycerides - blood | HIV Infections - drug therapy | Indinavir - adverse effects | Lipoproteins, LDL - blood | HIV Infections - metabolism | Indinavir - therapeutic use | Measurement | Complications and side effects | Dosage and administration | Blood lipids | Health aspects | HIV infection
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2008, Volume 358, Issue 20, pp. 2095 - 2106
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2013, Volume 8, Issue 5, p. e63623
Background: Lipoatrophy and/or central fat gain are observed frequently in patients on antiretroviral therapy (ART). Both are assumed to be antiretroviral... 
PROTEASE INHIBITOR | NUCLEOSIDE-SPARING REGIMEN | THYMIDINE ANALOG | MULTIDISCIPLINARY SCIENCES | MITOCHONDRIAL-FUNCTION | HIV-1-INFECTED PATIENTS | INFECTED PATIENTS | RANDOMIZED COMPARATIVE TRIAL | BODY-COMPOSITION | HUMAN-IMMUNODEFICIENCY-VIRUS | LIMB FAT | HIV Protease Inhibitors - adverse effects | Torso | Adiposity - drug effects | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Tomography, X-Ray Computed | Absorptiometry, Photon | Reverse Transcriptase Inhibitors - adverse effects | Drug-Related Side Effects and Adverse Reactions | Subcutaneous Fat - drug effects | Lipodystrophy - chemically induced | Intra-Abdominal Fat - drug effects | Lipodystrophy - diagnostic imaging | Complications and side effects | Highly active antiretroviral therapy | Care and treatment | Protease inhibitors | AIDS treatment | Proteases | DNA polymerases | Stavudine | Research | HIV (Viruses) | HIV infection | Antiretroviral drugs | Antiviral agents | RNA-directed DNA polymerase | Toxicity | Clinical trials | Proteinase inhibitors | Thymidine | Patients | Efavirenz | Antiretroviral therapy | Switching | Tenofovir | Side effects | Acquired immune deficiency syndrome--AIDS | Lipoatrophy | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Human immunodeficiency virus--HIV | Abacavir | Lipodystrophy | Zidovudine | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2018, Volume 13, Issue 6, p. e0198447
Background Nearly all newly infected children acquire Human Immunodeficiency virus (HIV) via mother-to-child transmission (MTCT) during pregnancy, labour or... 
CONSISTENCY | INTERVENTIONS | EFFICACY | INCONSISTENCY | MULTIDISCIPLINARY SCIENCES | PRETERM BIRTH | PREGNANT-WOMEN | RISK | 1ST TRIMESTER | COHORT | EXPOSURE | Anti-HIV Agents - economics | Nevirapine - economics | Humans | Infant | Nevirapine - adverse effects | Lamivudine - adverse effects | Stavudine - economics | Congenital Abnormalities | Drug Therapy, Combination - adverse effects | Stavudine - adverse effects | Zidovudine - economics | Female | Network Meta-Analysis | Child | Infant, Newborn | Infant, Low Birth Weight | Abnormalities, Drug-Induced - epidemiology | Zidovudine - adverse effects | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | Drug Therapy, Combination - economics | Pregnancy | Pregnancy Complications, Infectious - drug therapy | Stillbirth - epidemiology | HIV Infections - drug therapy | Lamivudine - economics | Infectious Disease Transmission, Vertical - statistics & numerical data | Perinatal Care - economics | Benzoxazines - economics | Infectious Disease Transmission, Vertical - prevention & control | Antiviral agents | Maternal-fetal exchange | Patient outcomes | Labor, Complicated | HIV patients | Birth defects | Risk factors | Prevention | Complications and side effects | Maternal health services | Disease transmission | Pregnant women | Dosage and administration | Drug therapy | Health aspects | Methods | Drugs | Nevirapine | Congenital defects | Clinical trials | Viruses | Risk | Systematic review | Infants | Stavudine | Efavirenz | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Human immunodeficiency virus--HIV | Safety | Children | Indinavir | Risk reduction | Lamivudine | Breast feeding | Patients | Antiretroviral therapy | Womens health | Birth weight | Bayesian analysis | Zidovudine | Acquired immune deficiency syndrome | AIDS | HIV | Human immunodeficiency virus
Journal Article
AIDS, ISSN 0269-9370, 05/2006, Volume 20, Issue 8, pp. 1163 - 1169
Background: The use fixed-dose combination (FDC) is a critical tool in improving HAART. Studies on the effectiveness of combined lamivudine, stavudine and... 
Developing countries | MSF | Survival analysis | Antiretroviral therapy | Generic fixed-dose combination | INFECTIOUS DISEASES | PROGNOSIS | antiretroviral therapy | TUBERCULOSIS | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | NEVIRAPINE | HIV-INFECTED PATIENTS | TRIAL | THERAPY | VIROLOGY | survival analysis | developing countries | PROGRAMS | generic fixed-dose combination | OUTCOMES | PROGRESSION | Lamivudine - administration & dosage | Medically Underserved Area | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | Nevirapine - therapeutic use | Stavudine - administration & dosage | Nevirapine - adverse effects | Reverse Transcriptase Inhibitors - administration & dosage | Drugs, Generic - therapeutic use | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | Stavudine - adverse effects | Stavudine - therapeutic use | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Antiretroviral Therapy, Highly Active - methods | Drug Administration Schedule | Anti-HIV Agents - adverse effects | Drugs, Generic - administration & dosage | Treatment Outcome | CD4 Lymphocyte Count | Drugs, Generic - adverse effects | Epidemiologic Methods | HIV Infections - drug therapy | Developing Countries | Nevirapine - administration & dosage
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2009, Volume 122, Issue 10, pp. S13 - S21
Journal Article
Journal Article
AIDS, ISSN 0269-9370, 01/2012, Volume 26, Issue 3, pp. 303 - 314
Journal Article